CD47 and acute myeloid leukemia: To identify potential therapeutic targets, many groups have reported cell surface proteins that are preferentially expressed on AML LSCs, including CD47 [5], CD44 [6], CD96 [7], CD123 [8, 9], CD99 [10], and TIM-3 [11, 12].